

REPORT FROM ANNUAL GENERAL MEETING 2025 OF QUALISYS HOLDING AKTIEBOLAG (PUBL)

14 May 2025 · Press release · Regulatory

Qualisys Holding Aktiebolag (publ) held its Annual General Meeting today, Wednesday 14 May 2025, at the company's premises at Kvarnbergsgatan 2 in Gothenburg, Sweden.

The following main resolutions were resolved upon at the Annual General Meeting.

Adoption of the income statement and balance sheet, and allocation of profits

The Annual General Meeting resolved to adopt the income statement and the balance sheet for the company and the group for the financial year 2024 in accordance with the presented annual report.

The Annual General Meeting resolved, in accordance with the Board of Directors' proposal, on a dividend of SEK 3.00 per share. The record date for payment of the dividend is 16 May 2025 and the dividend will be paid to the shareholders on 21 May 2025.

Discharge of liability

The Annual General Meeting resolved to discharge all individuals who had served as director, deputy director, or CEO of the company during 2024 from liability for the financial year 2024.

Board of Directors and auditor

The Annual General Meeting resolved, in accordance with shareholder's proposal, to re-elect the directors Peter Gille, Henrik Nyberg, Daniel Petersson, and Jenny Rosberg. Peter Gille was re-elected as chairperson of the Board of Directors. The Board of Directors thus consists of four directors without deputies.

The Annual General Meeting resolved, in accordance with the Board of Directors' proposal, to re-elect the registered audit firm Öhrlings PricewaterhouseCoopers AB (PwC) as auditor. It was noted that Johan Palmgren been appointed by PwC to continue as the auditor in charge.

Fees to the Board of Directors and auditor

The Annual General Meeting resolved, in accordance with shareholder's proposal, that fees to the Board of Directors shall be paid as follows.

The chairperson of the Board of Directors shall receive a fee of SEK 500,000 and each of the other directors elected by the Annual General Meeting shall receive a fee of SEK 225,000. No fee shall be paid to directors who are employed by the company or its group, or to directors who are not considered independent in relation to the company's major shareholders.

Fee to the auditor was resolved to be paid as per invoice approved by the company.

Establishment of a Nomination Committee and adoption principles for the Nomination Committee

The Annual General Meeting resolved, in accordance with the Board of Directors' proposal, to establish a Nomination Committee and to adopt principles for the Nomination Committee.

Adoption of guidelines for the remuneration to senior executives

The Annual General Meeting resolved, in accordance with the Board of Directors' proposal, to adopt guidelines for the remuneration to senior executives.

Long-term warrant programme through a directed issue of warrants of series 2025 /2028

The Annual General Meeting resolved, in accordance with the Board of Directors' proposal, on a long-term warrant programme through a directed issue of warrants of series 2025/2028.

Authorization to the Board of Directors to resolve on issue of new shares, warrants, and/or convertibles

The Annual General Meeting resolved, in accordance with the Board of Directors' proposal, to authorize the Board of Directors, on one or more occasions until the next Annual General Meeting, to resolve on issue of new shares, warrants, and/or convertibles corresponding to a dilution of not more than ten percent.

The complete proposals of the Board of Directors and the shareholder are available on the company's website [**Investor relations – Qualisys Investors**](#)

For further information, please contact:

Ingemar Pettersson, CEO
+46 31-336 94 18

Annelie Skafte Persson, CFO
+46 31-336 94 37

About Qualisys Holding AB (publ)

Qualisys is a leading provider of motion capture technology and has a long history of supplying research, engineering, entertainment, and sports facilities with high-end camera systems and expertise in capturing and analyzing movements. Qualisys offers a wide range of products and services with its headquarter in Gothenburg, Sweden, and operations in Chicago, Singapore and Shanghai. Qualisys is certified according to ISO 9001:2015, the clinical products are compliant with Medical Device Directive 93/42/EEC and have FDA clearance (K171547).

Qualisys is listed on Nasdaq First North Premier Growth Market. The company's Certified Adviser is Svensk Kapitalmarknadsgranskning AB.